Last updated: Oct 4, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07419841 | 1 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Unknown mechanism |
| NCT06999694 | 2 | Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC | CTLA-4 + PD-L1 -- immune checkpoint inhibitors (tremelimumab and durvalumab) combined with proton radiotherapy |
| NCT06999707 | 2 | Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC | PD-L1 + CTLA-4 -- immune checkpoint blockade (immune checkpoint inhibitors) |
| NCT06893887 | — | Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma | PD-L1 + VEGFR2 + JAK/STAT + TGF-beta -- bispecific antibody plus tyrosine kinase inhibitors and small molecule modulator |
| NCT06339424 | 2 | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma | PD-L1 + VEGF -- immune checkpoint inhibitor plus anti-angiogenic antibody |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 35 |
| Tianjin Medical University Cancer Institute and Hospital | 20 |
| Tongji Hospital | 16 |
| Second Affiliated Hospital of Guangzhou Medical University | 16 |
| West China Hospital | 14 |
Countries/regions with the most active trial sites for hepatocellular carcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Oct 10, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | GLP-1 receptor -- receptor agonist (GLP-1 RA) |
| Oct 1, 2026 | NCT07835737 | Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma | PD-L1 + VEGF -- bispecific antibody (Atezolizumab and Bevacizumab); Folic Acid -- metabolic supplement |
| Sep 30, 2026 | NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | VEGF -- monoclonal antibody (Bevacizumab); PD-1 -- immune checkpoint inhibitor (Sintilimab); Unknown target -- SYS6090 and SYS6043 mechanism unclear |
| Sep 1, 2026 | NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | PD-1 + CTLA-4 + nucleoside analog -- immune checkpoint inhibitor plus nucleoside analog |
| Sep 2026 | NCT07430202 | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | DNAJB1-PRKACA fusion kinase -- peptide vaccine plus glutamine antagonist plus PD-1 and CTLA-4 immune checkpoint inhibitors |
| Aug 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Fibroblast activation protein (FAP) -- PET imaging tracer targeting FAP (radiotracer) |
| Jul 20, 2026 | NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | CTLA-4 + PD-1 + VEGF -- combination of immune checkpoint inhibitors and anti-angiogenic antibody |
| Jul 2026 | NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | Autologous immune cells -- cytokine-induced killer cell therapy |
You've seen the hepatocellular carcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.